| Name | Tenofovir alafenamide fumarate |
|---|---|
| Synonyms |
Tenofovir alafenamide fumarate, 1:1
TAF GS-7340 fumarate Isopropyl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate (2E)-2-butenedioate (1:1) L-Alanine, N-[(S)-[(1S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2E)-2-butenedioate (1:1) Tenofovir alafenamide fumarate1:1 GS-7340 (fumarate) |
| Description | Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. |
|---|---|
| Related Catalog | |
| Target |
HIV-1, NRTIs[1] |
| In Vitro | Tenofovir alafenamide antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for TAF and 6.4 nM for AZT[2]. |
| In Vivo | Tenofovir alafenamide hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF)[1]. |
| References |
| Molecular Formula | C25H33N6O9P |
|---|---|
| Molecular Weight | 592.538 |
| Exact Mass | 592.204651 |
| PSA | 227.89000 |
| LogP | 3.65680 |
| Storage condition | 2-8℃ |